In high-lev­el reshuf­fle, Roche gives James Sabry the glob­al reins on deal-mak­ing — over­see­ing pRED and gRED

In the 9 years since Roche bought up all of Genen­tech, the Swiss phar­ma gi­ant has been care­ful to leave its lega­cy R&D group pRED sep­a­rate from the folks at the gRED op­er­a­tions they ac­quired in San Fran­cis­co. But in a star­tling shift to­day the ex­ec­u­tive team knit­ted the two groups’ BD teams in­to one, com­bin­ing part­ner­ing ops and mak­ing Genen­tech’s James Sabry their glob­al deal czar for phar­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.